Alexion Pharmaceuticals P/E Ratio

Alexion Pharmaceuticals (ALXN) currently reports a P/E ratio of 66.36. That is above the Healthcare sector average of 25.3. Use the charts on this page to explore Alexion Pharmaceuticals's P/E ratio history and peer comparisons.

Alexion Pharmaceuticals's P/E ratio of 66.36 is higher than the Healthcare sector average of 25.3. That is roughly 162.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Alexion Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 66.36, ALXN can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 66.36, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.3. From there, open related valuation or income-statement pages for Alexion Pharmaceuticals, and consider following ALXN for alerts when major investors trade the stock.

Alexion Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows 66.36 versus a sector average near 25.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALXN with unrelated industries.